11/7/2023 0 Comments Rcmd form of mds![]() ![]() ![]() ![]() Mean WBC count differed between all subgroups (RARS: 6.1 RCMD: 4.4 RCMD-RS: 5.3×10(9)/l RARS vs RCMD p80% of patients show a good risk cytogenetic profile making prognostication according to karyotype relevant only in a small subset of patients. Mean age (RARS: 71.8 RCMD: 70.1 RCMD-RS: 72.6 yrs) reached significant difference between RARS vs RCMD (p=0.020) and between RCMD vs RCMD-RS (p=0.004). Results: Sex ratio (male preponderance in all subtypes male/female ratio 1.9 in the whole cohort) did not differ significantly between the 3 MDS subgroups. Cytogenetic risk groups were defined according to the International Prognostic Scoring System (IPSS Greenberg et al., 1997). Study Design: To investigate the clinical impact and genetic background of these MDS subtypes, we studied outcomes, cytogenetics, and molecular genetics in 1082 de novo MDS pts (153 RARS, 606 RCMD, 323 RCMD with ring sideroblasts ≥15% termed “RCMD-RS“): 703 m/379 f median age, 73.1 yrs 21.0–90.4 yrs. One aim of this study was to evaluate whether or not a separation with respect to ring sideroblasts is reasonable. In 2008 the WHO classification combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (with ring sideroblasts ≥15%) thus not separating according to ring sideroblasts anymore in MDS with multilineage dysplasia, while the category refractory anemia with ring sideroblasts (RARS) was maintained separately. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |